“…[34,111,112,113,114,115] Araújo et al , (2014) [115] have demonstrated that in chitosan coated nanocarriers (e.g., poly(lactide- co -glycolide), solid lipid nanoparticles and porous silicon), a more sustained release of payload (e.g., glucagon like peptide-1) with enhanced bioavailability resulted from its mucoadherent tendency. Thus, these DDS can be utilized in ocular [116,117,118,119], buccal [120,121,122,123], nasal [124,125,126,127], pulmonary [128,129,130,131], vaginal [132,133,134,135,136], or rectal [137,138,139,140] delivery, for eliciting a therapeutic effect either locally or systemically [13,114,141].…”